|Erika Fullwood Augustine, MD, FAAN
||Biomarin Pharmaceutical - Consultant Regenxbio - Consultant. Abeona Therapeutics - clinical trial planning agreement
Neurocrine Biosciences - site investigator.
|Peter A. Calabresi, MD, FAAN
||Dr. Calabresi has nothing to disclose.
|Susan Fox, MD
||Dr. Fox has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Avanir, Biotie, Britannia, Cynapsus, Kyowa, Sunovion, and Zambon, honoraria from the International Parkinson and Movement Disorder Society, CHDI and American Academy of Neurology; and from UHN Dept of Medicine Practice Plan as an employee. Dr. Fox has received research support from Michael J Fox Foundation for Parkinson Disease research, NIH, Parkinson Canada and Toronto Western Hospital Foundation.
|Cynthia L. Harden, MD
||Dr. Harden has nothing to disclose.
|Brett M. Kissela, MD, FAAN, MS
||Dr. Kissela has nothing to disclose.
|Paul M. Vespa, MD, FAAN
||Speaker for Medicines Company, consultant for EDGE, Intouch, GE, SAGE, C3O.